Currently, there are 99.32M common shares owned by the public and among those 87.98M shares have been available to trade.
The company’s stock has a 5-day price change of -14.87% and -22.90% over the past three months. AQST shares are trading -35.67% year to date (YTD), with the 12-month market performance down to -30.40% lower. It has a 12-month low price of $2.20 and touched a high of $5.80 over the same period. AQST has an average intraday trading volume of 1.39 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -16.70%, -17.92%, and -39.45% respectively.
Institutional ownership of Aquestive Therapeutics Inc (NASDAQ: AQST) shares accounts for 37.98% of the company’s 99.32M shares outstanding.
It has a market capitalization of $227.44M and a beta (3y monthly) value of 1.97. The earnings-per-share (ttm) stands at -$0.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.44% over the week and 6.56% over the month.
Earnings per share for the fiscal year are expected to decrease by -30.07%, and 14.26% over the next financial year. EPS should shrink at an annualized rate of 13.68% over the next five years, compared to 27.90% over the past 5-year period.
Looking at the support for the AQST, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on December 17, 2024, with the firm’s price target at $17. Leerink Partners coverage for the Aquestive Therapeutics Inc (AQST) stock in a research note released on May 10, 2024 offered a Outperform rating with a price target of $8. Piper Sandler was of a view on April 11, 2024 that the stock is Overweight, while Raymond James gave the stock Outperform rating on March 28, 2024, issuing a price target of $7. RBC Capital Mkts on their part issued Outperform rating on April 07, 2021.
